The European Orthopedic Hip and Knee Implant Markets, 2003-2008
The European orthopedic implants and trauma products market consists of hip, knee, shoulder, and small joint reconstruction and replacements; fracture fixation and bone growth stimulation; bone graft substitutes and growth factors; and bone cements segments. "European Markets for Orthopedic Implants and Trauma Products", a report published in October 2004 by Windhover/Medtech Insight, surveys and forecasts these markets in France, Germany, Italy, Spain, and the UK. Within these countries there is considerable potential for new and innovative technologies such as bone graft substitutes and the use of resorbable implants in trauma. However, medical-based evidence must show added value and improvement in a patient's quality of life before such innovations will be broadly accepted. Meeting health care regulatory authorities' compliance criteria while not burdening health care payers with dramatic increases in reimbursement budgets is viewed as a major driving factor within Europe.
The European orthopedic implants and trauma products market
consists of hip, knee, shoulder, and small joint reconstruction and
replacements; fracture fixation and bone growth stimulation; bone
graft substitutes and growth factors; and bone cements segments.
European Markets for Orthopedic Implants and Trauma
Products, a report published in October 2004 by
Windhover/Medtech Insight, surveys and forecasts these markets in
France, Germany, Italy, Spain, and the United Kingdom.
Within these countries there is considerable potential for new and innovative technologies such as bone graft substitutes and the use...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.